TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38236314
Drug: Eptinezumab 300
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptinezumab 300 mg
Study: 34714125
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care with mother's own milk (MOM)
Study: 33783495
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard treatment model)
Study: 35413022
Drug: SARS-CoV-2 infection
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 infection (defined as COVID-19 clinical diagnosis or presence of SARS-CoV-2 IgG/IgA antibodies)
Study: 36817782
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard antibiotic treatment)
Study: 35225460
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml ONS twice a day
Study: 32660299
Drug: Adjunctive low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive low-dose transdermal testosterone cream
Study: 34298589
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin
Study: 34019513
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of migraine headaches
Study: 34758056
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic Acid (HA) compound filling plus mesotherapy
Study: 34758056
Drug: Botulinum Toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum Toxin A (BTX-A) injection
Study: 39001910
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (AC)
Study: 36484803
Drug: Test methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test methotrexate tablet (2.5 mg) under fasting conditions
Study: 32018065
Drug: Schema therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schema therapy
Study: 33852940
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg/day)
Study: 35277166
Drug: 0.375% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% ropivacaine with 1 µg/kg dexmedetomidine in 20 ml for ESPB (Group E)
Study: 36083489
Drug: Shugan Jieyu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shugan Jieyu capsule
Study: 34674843
Drug: Intravenous piperacillin/tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous piperacillin/tazobactam for 24–48 h followed by 10 days of oral ciprofloxacin/metronidazole
Study: 34388414
Drug: Intravenous thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous thiamine (200 mg every 12 hours for up to 14 doses)
Study: 32799851
Drug: Single high-molecular-weight
Normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single high-molecular-weight hyaluronic acid (HMW-HA) injection (Arthromac)
Study: 32799851
Drug: Triple low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple low-molecular-weight hyaluronic acid (LMW-HA) injections (Hyalgan)
Study: 36035829
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (disposable ophthalmic single-port operation cloth)
Study: 32580990
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered prednisolone 50 mg per day for up to 3 days, tapering to cessation over 10 days, in addition to guideline advice.
Study: 33853550
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiotherapy (SABR) at escalating doses starting from 6 Gy × 2 weekly fractions to a maximum of 6 Gy × 5 weekly fractions (dose level 4)
Study: 33398094
Drug: Extracorporeal photopheresis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal photopheresis (ECP) with steroids
Study: 32950748
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg subcutaneous mirikizumab (maintenance therapy)
Study: 39566051
Drug: Hyperbaric Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric Oxygen Therapy (HBOT)
Study: 33836310
Drug: Thrice-weekly PRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly PRT plus impact exercise training
Study: 33431967
Drug: 15% CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% CO2 treatment
Study: 33431967
Drug: High-CO2 concentration
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-CO2 concentration formulation
Study: 33431967
Drug: NaOH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaOH treatment (to correct medium acidification)
Study: 33431967
Drug: Knockdown of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knockdown of H+-sensing G protein-coupled receptor 65
Study: 33504555
Drug: Immunotherapy (dinutuximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (dinutuximab + GM-CSF + IL2)
Study: 35432566
Drug: ZuoJin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZuoJin Pill (ZJP)
Study: 37141104
Drug: Water infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water infusion
Study: 32844196
Drug: Levodopa therapy
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa therapy
Study: 36341753
Drug: More intensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intensive treatment (systolic blood pressure target <120 mm Hg)
Study: 36341753
Drug: Less intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intensive treatment (systolic blood pressure target 140-180 mm Hg)
Study: 38778383
Drug: treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as usual
Study: 35357058
Drug: Itopride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride (100 mg t.i.d.)
Study: 33829609
Drug: Axitinib and
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib and carotuximab (TRC105) combination therapy
Study: 33947608
Drug: Axitinib monotherapy
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib monotherapy
Study: 33056965
Drug: Retinalamin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinalamin treatment course every 6 months
Study: 36653090
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9 inhibitor (evolocumab) 140 mg subcutaneous injection
Study: 36653090
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9 inhibitor (evolocumab)
Study: 32992440
Drug: 0.9 g·kg·FFM−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g·kg·FFM−1 GLN (HIGH)
Study: 32992440
Drug: 0.6 g·kg·FFM−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g·kg·FFM−1 GLN (MED)
Study: 33710659
Drug: Video‐to‐home cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video‐to‐home cognitive‐behavioral therapy
Study: 34003285
Drug: Cognitive Functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Functional Therapy+ (CFT+) with psychologist support and option of additional usual care
Study: 36700035
Drug: Lacticaseibacillus rhamnosus
Normalized name: Lacticaseibacillus rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain, orally administrated at 1.0×10^10 colony-forming units once daily for 10 days
Study: 34107173
Drug: Avelox 400
Normalized name: Avelox 400mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelox 400 mg
Study: 35805767
Drug: Dental care,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental care, anticipatory guidance on oral health and dietary intake, motivational interviewing
Study: 34657222
Drug: Ampreloxetine 5
Normalized name: Ampreloxetine
DrugBank: Ampreloxetine (DB15348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampreloxetine 5 mg and 10 mg
Study: 34657222
Drug: Ampreloxetine (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampreloxetine (median dose 15 mg)
Study: 34657222
Drug: Ampreloxetine (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampreloxetine (median dose 10 mg)
Study: 33610175
Drug: Chloroprocaine HCl
Normalized name: chloroprocaine HCl
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroprocaine HCl 1% at 30 mg
Study: 33610175
Drug: Chloroprocaine HCl
Normalized name: chloroprocaine HCl
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroprocaine HCl 1% at 40 mg
Study: 33610175
Drug: Chloroprocaine HCl
Normalized name: chloroprocaine HCl
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroprocaine HCl 1% at 50 mg
Study: 32662036
Drug: Bisphosphonate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate treatment duration less than 1 year
Study: 34592778
Drug: Combination (Arsenicum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (Arsenicum album 30c, Bryonia alba 30c, Gelsemium sempervirens 30c, and Influenzinum 30c)
Study: 32514196
Drug: Short treatment
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short treatment regimen (9 to 11 months)
Study: 32514196
Drug: Long treatment
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long treatment regimen (20 to 22 months)
Study: 35041809
Drug: 5% CBLH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% CBLH (single injection)
Study: 35041809
Drug: 10% CBLH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% CBLH (single injection)
Study: 35041809
Drug: 15% CBLH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% CBLH (4-time injections)
Study: 35041809
Drug: Phosphate buffered
Normalized name: Phosphate Buffered Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline (1 injection)
Study: 33119068
Drug: 3AV (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3AV (10 μg)
Study: 33119068
Drug: 1AV (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1AV (20 µg)
Study: 35962934
Drug: Acid-reducing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-reducing agents (ARAs)
Study: 34098984
Drug: Dihydroartemisinin-piperaquine, full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine, full course delivered by trained village health workers to all residents of compounds with reported clinical cases.
Study: 32895281
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (target Hb levels of 70-90 g/L)
Study: 35481441
Drug: Dietary 25-hydroxyvitamin
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary 25-hydroxyvitamin D3 at 4.9 µg/kg
Study: 35481441
Drug: Dietary 25-hydroxyvitamin
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary 25-hydroxyvitamin D3 at 8.4 µg/kg
Study: 35481441
Drug: Dietary 25-hydroxyvitamin
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary 25-hydroxyvitamin D3 at approximately 5.0 µg/kg
Study: 37094892
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy
Study: 35347400
Drug: Immediate spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate spa therapy
Study: 35347400
Drug: Usual treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatments (Control)
Study: 32534949
Drug: Standard calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard calorie administration based on predictive equations (20-25 kcal/kg ideal body weight/day)
Study: 36278294
Drug: TS-P1 45
Normalized name: ALT-P1
DrugBank: ALT-P1 (DB18485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-P1 45 mg
Study: 36278294
Drug: CR-033P 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR-033P 90 mg
Study: 36278294
Drug: CR-043P 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR-043P 90 mg
Study: 34973935
Drug: Recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant FSH administered at 20:00 h
Study: 34973935
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist administered at 08:00 h
Study: 32940642
Drug: 0.1 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mmol/L of α-MSH treatment
Study: 36468983
Drug: SNRI-Duloxetine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNRI-Duloxetine therapy at a dose of 60 mg per day for 8 weeks
Study: 36468983
Drug: Trimebutine therapy
Normalized name: trimebutine
DrugBank: Trimebutine (DB09089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimebutine therapy at a dose of 600 mg per day
Study: 34087225
Drug: COSMOS intervention
Normalized name: Cosmos sulphureus flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: COSMOS intervention (multicomponent intervention including staff training in communication, pain treatment, medication review, organization of activities, and safety) for 4 months
Study: 37414137
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy
Study: 37409838
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 mg kg ‐1 bolus followed by 4 mg kg ‐1 h ‐1 infusion)
Study: 37409838
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 µg kg ‐1 followed by 2 µg kg ‐1 h‐1 infusion)
Study: 35168636
Drug: Date palm
Normalized name: date palm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Date palm capsule
Study: 32976523
Drug: L-carnitine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine infusion (28mg/kg) with Intralipid (20%, 90mL/h)
Study: 35640636
Drug: Ad26.ZEBOV, MVA-BN-Filo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen
Study: 36464853
Drug: Lenvatinib 18
Normalized name: lenvatinib 18 MG Daily Dose 30 Day Supply Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 18 mg/day
Study: 32403115
Drug: Immediate iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate iron therapy
Study: 32403115
Drug: Delayed iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed iron therapy (28-day delay)
Study: 33992100
Drug: Spinal manual
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manual therapy
Study: 35470195
Drug: Corticosteroid nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid nerve root injections
Study: 35226756
Drug: solution-focused psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution-focused psychotherapy (n=97)
Study: 33607803
Drug: therapy of
Normalized name: Ep-100 (conjugate of luteinizing hormone-releasing hormone with a cationic .alpha.-helical peptide for therapy of lhrh-expressing tumors)
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapy of 'combination 3 methods progression'
Study: 35451636
Drug: Forced diuresis
Normalized name: benzalkonium chloride Topical Solution [Clean Force]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced diuresis using furosemide 1 mg/kg (GII)
Study: 33175623
Drug: Eosin 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eosin 2% solution
Study: 35477616
Drug: REL-1017 25
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: REL-1017 25 mg
Study: 35477616
Drug: REL-1017 50
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: REL-1017 50 mg
Study: 35145043
Drug: 14-day bismuth-based
Normalized name: bismuth subcitrate 14 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day bismuth-based quadruple therapy (n=102)
Study: 35130447
Drug: Pre-clinical screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-clinical screening of drugs
Study: 33051255
Drug: Low-dose SCS
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SCS (initial dose ≤ 40 mg prednisone equivalent/d)
Study: 33051255
Drug: Medium-dose SCS
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose SCS (initial dose = 40-100 mg prednisone equivalent/d)
Study: 33154086
Drug: Remote Directly
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote Directly Observed Therapy (R‐DOT)
Study: 34340097
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg rectal, administered twice within the same day, starting at twelve hours after triggering)
Study: 35763658
Drug: Olanzapine 5
Normalized name: olanzapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5 mg
Study: 35961468
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT–I)
Study: 32988690
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard vaccine education)
Study: 35281612
Drug: High-energy shockwave
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy shockwave therapy (ESWT)
Study: 39487326
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% monotherapy
Study: 36150356
Drug: PDMP alert
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDMP alert for high dose
Study: 32415846
Drug: Sertraline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (400 mg/day for 8 weeks, then tapered)
Study: 32825982
Drug: Resistance Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance Training with Curcumin Supplement (RTC)
Study: 32825982
Drug: Curcumin Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin Supplement (C)
Study: 37626303
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline infusion)
Study: 33032908
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 600 mg for 80 days
Study: 33896706
Drug: Smartphone-based cardiovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based cardiovascular risk reduction program using the 'BreastMate' application as an adjunct to standard care.
Study: 37159200
Drug: Mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (600 mg)
Study: 34324880
Drug: Enteral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral iron supplementation (mean 4.8 mg/kg/d in Epo group, 3.6 mg/kg/d in placebo group) at 60 days
Study: 34324880
Drug: Placebo (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mean 3.6 mg/kg/d) at 60 days
Study: 34324880
Drug: Epo (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epo (mean 4.8 mg/kg/d) at 60 days
Study: 34324880
Drug: Iron dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dose at 90 days
Study: 33298149
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparins at 50 IU anti-Xa/kg twice daily or 75 IU anti-Xa twice daily in combination with aprotinin
Study: 36214614
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) treatment
Study: 35707984
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure Therapy (CPAP)
Study: 35707984
Drug: High-Flow Nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Nasal Cannula Therapy (HFNC)
Study: 33749321
Drug: OB-002H gel
Normalized name: Obe-cel
DrugBank: Obecabtagene autoleucel (DB17362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OB-002H gel (5 vaginal daily doses)
Study: 33749321
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo (5 vaginal daily doses)
Study: 33749321
Drug: OB-002H gel
Normalized name: Obe-cel
DrugBank: Obecabtagene autoleucel (DB17362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OB-002H gel
Study: 35315622
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion
Study: 38107550
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (IVIG)
Study: 33213527
Drug: Levamlodipine 5
Normalized name: levamlodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamlodipine 5 mg (fasted)
Study: 33213527
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg (fasted)
Study: 33213527
Drug: Levamlodipine 5
Normalized name: levamlodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamlodipine 5 mg (fed)
Study: 34706311
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg subcutaneous every 6 months) added to intensive urate-lowering therapy (ULT)
Study: 34706311
Drug: Intensive urate-lowering
Normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intensive urate-lowering therapy (ULT) alone
Study: 32011496
Drug: Phellinus linteus
Normalized name: PHELLINUS LINTEUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phellinus linteus (PL) 2000 mg
Study: 32011496
Drug: Phellinus linteus
Normalized name: PHELLINUS LINTEUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phellinus linteus (PL) 1000 mg